We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert Questions Pfizer’s Reporting of Neurontin Trial Results
Expert Questions Pfizer’s Reporting of Neurontin Trial Results
November 13, 2009
A medical journal review that found selective publishing of study data for Pfizer’s Neurontin for off-label use — when results were not statistically significant for the primary outcome the protocol specified — reveals a practice that should at least be justified and documented, an expert says.